4.5 Article

Transcription factor ELF4 promotes development and function of memory CD8+ T cells in Listeria monocytogenes infection

Journal

EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 44, Issue 3, Pages 715-727

Publisher

WILEY
DOI: 10.1002/eji.201343775

Keywords

Bacterial infection; CD8(+) T cells; ELF4; Memory

Categories

Funding

  1. National Institutes of Health [R01-AI077536, R01-AI077536-02S1]

Ask authors/readers for more resources

Most differentiated CD8(+) T cells die off at the end of an infection, revealing two main subsets of memory T cells central and effector memory which can be found in lymphoid tissues or circulating through nonlymphoid organs, respectively. The cell intrinsic regulation of the differentiation of CD8(+) T cells to effector and central memory remains poorly studied. Herein, we describe a novel role of the ETS transcription factor ELF4 in the development and function of memory CD8(+) T cells following infection with Listeria monocytogenes. Adoptively transferred Elf4(-/-) naive CD8(+) T cells produced lower numbers of effector memory CD8(+) T cells despite a normal pool of central memory. This was caused by suboptimal priming and decreased survival of CD8(+) T cells at the peak of response while enhanced Notch1 signaling and upregulation of eomesodermin correlated with normal development of Elf4(-/-) central memory. Finally, loss of ELF4 impaired the expansion of both central and effector memory CD8(+) T cells in a recall response by also activating Notch1 signaling. Altogether, ELF4 emerges as a novel transcriptional regulator of CD8(+) T-cell differentiation in response to infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Cell & Tissue Engineering

Concise Review: Regulation of Self-Renewal in Normal and Malignant Hematopoietic Stem Cells by Kruppel-Like Factor 4

Chun S. Park, Andrew Lewis, Taylor Chen, Daniel Lacorazza

STEM CELLS TRANSLATIONAL MEDICINE (2019)

Review Oncology

Chimeric Antigen Receptors for T-Cell Malignancies

Lauren D. Scherer, Malcolm K. Brenner, Maksim Mamonkin

FRONTIERS IN ONCOLOGY (2019)

Article Oncology

Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma

Sai Arun Batra, Purva Rathi, Linjie Guo, Amy N. Courtney, Julien Fleurence, Julien Balzeau, Rahamthulla S. Shaik, Thao P. Nguyen, Meng-Fen Wu, Shaun Bulsara, Maksim Mamonkin, Leonid S. Metelitsa, Andras Heczey

CANCER IMMUNOLOGY RESEARCH (2020)

Article Biotechnology & Applied Microbiology

Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections

Henning Olbrich, Sebastian J. Theobald, Constanze Slabik, Laura Gerasch, Andreas Schneider, Michael Mach, Thomas Shum, Maksim Mamonkin, Renata Stripecke

HUMAN GENE THERAPY (2020)

Editorial Material Biotechnology & Applied Microbiology

CRISPR-Edited Immune Effectors: The End of the Beginning

Feiyan Mo, Helen E. Heslop, Maksim Mamonkini

MOLECULAR THERAPY (2020)

Article Biotechnology & Applied Microbiology

Engineered off-the-shelf therapeutic T cells resist host immune rejection

Feiyan Mo, Norihiro Watanabe, Mary K. McKenna, M. John Hicks, Madhuwanti Srinivasan, Diogo Gomes-Silva, Erden Atilla, Tyler Smith, Pinar Ataca Atilla, Royce Ma, David Quach, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Summary: Engineered T cells targeting allogeneic lymphocytes through the alloimmune defense receptor (ADR) demonstrated effective tumor eradication in mouse models of hematopoietic and solid cancers, offering a potential 'off-the-shelf' therapy for immunocompetent recipients. The ADR selectively recognizes the 4-1BB receptor transiently expressed on activated lymphocytes, allowing for prolonged persistence and therapeutic benefit of rejection-resistant allogeneic T cells. This approach may provide a promising solution to the challenges of manufacturing autologous T cells for cancer therapy.

NATURE BIOTECHNOLOGY (2021)

Editorial Material Hematology

Detonating T-ALL

Maksim Mamonkin

BLOOD (2020)

Article Oncology

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia

Pinar Ataca Atilla, Mary K. McKenna, Haruko Tashiro, Madhuwanti Srinivasan, Feiyan Mo, Norihiro Watanabe, Brian Wesley Simons, Alexandra McLean Stevens, Michele S. Redell, Helen E. Heslop, Maksim Mamonkin, Malcolm K. Brenner, Erden Atilla

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Cell & Tissue Engineering

Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy

Pinar Ataca Atilla, Mary K. McKenna, Norihiro Watanabe, Maksim Mamonkin, Malcolm K. Brenner, Erden Atilla

Summary: This study demonstrates that combinatorial targeting of CD33 or CD123 and CLL-1 using CAR T cells can effectively control the growth of heterogeneous AML tumors and improve survival rates.

CYTOTHERAPY (2022)

Article Cell & Tissue Engineering

Kruppel-like Factor 4 Supports the Expansion of Leukemia Stem Cells in MLL-AF9-driven Acute Myeloid Leukemia

Andrew Henry Lewis, Cory Seth Bridges, David Neal Moorshead, Taylor J. Chen, Wa Du, Barry Zorman, Pavel Sumazin, Monica Puppi, H. Daniel Lacorazza

Summary: In this study, we found that KLF4 plays an important role in acute myeloid leukemia (AML) and is related to the self-renewal and stemness of leukemia stem cells. Our experiments demonstrated that loss of KLF4 in leukemic granulocyte-macrophage progenitors (L-GMP) significantly reduced the frequency of leukemia stem cells and affected the cell cycle. We also found that upregulation of the DDX58 gene is associated with KLF4 loss and may be involved in this process. Therefore, KLF4 promotes leukemia progression in AML by regulating gene expression to support the division and stemness of leukemia stem cells.

STEM CELLS (2022)

Editorial Material Hematology

CD7 CAR: sword and shield

M. Paulina Velasquez, Maksim Mamonkin

Summary: The article introduces a novel approach to generate autologous CD7-specific CAR T cells for treating patients with T-lineage malignancies. The research shows that this method has shown good efficacy in patients.

BLOOD (2022)

Article Hematology

Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia

Cory Seth Bridges, Taylor J. Chen, Monica Puppi, Karen R. Rabin, H. Daniel Lacorazza

Summary: Novel drugs, such as OTSSP167, have been shown to have antileukemic capacity in children with high-risk T-cell acute lymphoblastic leukemia (T-ALL). OTSSP167 inhibits MAP2K7 kinase activity and the downstream substrate, JNK, leading to apoptosis and cell cycle arrest in T-ALL cell lines. It also exhibits synergistic effects when combined with other drugs and shows potential as an adjuvant treatment to enhance response and reduce relapses in pediatric T-ALL.

BLOOD ADVANCES (2023)

Editorial Material Hematology

Splendid isolation

Dimitrios Laurin Wagner, Maksim Mamonkin

BLOOD (2023)

Article Hematology

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy

Jay A. Read, Rayne H. Rouce, Feiyan Mo, Maksim Mamonkin, Katherine Y. King

Summary: This study investigates the mechanism of delayed bone marrow recovery following CAR-T therapy. The results indicate that the elevation of inflammatory cytokines after CAR-T therapy leads to apoptosis and depletion of hematopoietic stem and progenitor cells, resulting in cytopenias. This finding has important implications for the safety and efficacy of CAR-T therapy.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Review Oncology

Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Premal D. Lulla, Maksim Mamonkin, Malcolm K. Brenner

CANCER JOURNAL (2019)

No Data Available